Clinical trial
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009, When Administered to Elderly Subjects
NCT00734734 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009, When Administered to Elderly Subjects
- Lead sponsor
- Novartis Vaccines
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2008
- Completion date
- July 31, 2008
- Enrollment
- 64 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
interpandemic influenza